Editas Medicine vs Sutro Biopharma
Sutro Biopharma is the larger business, with $102m of revenue in fiscal 2025 against $40.5m for Editas Medicine (2.5 times as much). Sutro Biopharma grew faster (65.2% against 25.4%). Sutro Biopharma kept more of each dollar of sales as profit: a net margin of -186.5% against -395.0%.
| Latest fiscal year | Editas MedicineEDIT, 2025 | Sutro BiopharmaSTRO, 2025 |
|---|---|---|
| Revenue | $40.5m | $102m |
| Revenue growth | 25.4% | 65.2% |
| Net income | −$160m | −$191m |
| Operating margin | -394.9% | — |
| Net margin | -395.0% | -186.5% |
| Return on equity | -198.1% | — |
| Free cash flow | −$166m | −$177m |
| Cash | $147m | $58.1m |
| Total debt | $58.6m | $0 |
| Debt to equity | 214.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 87 | 137 |
| Market value | $252m | $151m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 14 sales | 0 buys, 0 sales |